Taken continuously through an infection season, standardized Echinacea extracts are linked to fewer respiratory infections and complications, and less antibiotic use. Started at symptom onset, the effect on illness length is small and inconsistent. Species, plant part, and extraction differ enormously, and much positive evidence carries maker ties. (Full Review)

Protocol

Prevention, standardized fresh-plant extract

2,400 mg daily

Fresh Echinacea purpurea extract, three doses daily through the season

Acute escalation

About 4,000 mg daily

Same preparation, up to 10 days during an active infection

Half-life and dosing frequency

3–4 divided doses

Short half-life rules out once-daily dosing; tablets underdeliver vs tincture

Time to effect

Fewer respiratory infections

Across an infection season

Effect builds with continued adherence rather than fading

Faster viral clearance

First days of dosing

On the escalated acute dose; not independently replicated

Reduced anxiety

Seven days

Low-dose Echinacea angustifolia root extract

Benefits

High: Fewer respiratory infections on continuous use; less antibiotic use and fewer complications

Medium: Faster viral clearance during acute respiratory infection

Low: Shorter cold duration when treatment starts early; reduced anxiety and improved emotional wellbeing

Speculative: Longer survival, killer-cell recovery in aging mice; virus inactivation; damped cytokines

Contraindications

Prior severe reaction to Echinacea or Asteraceae plants (ragweed, chamomile)

Poorly controlled asthma; atopy with prior anaphylaxis

Solid-organ transplant on immunosuppression

Pregnancy and lactation

Active autoimmune disease on systemic immunomodulators

Children under 2 years

Key Interactions

CYP3A4 substrates (midazolam, ciclosporin)

CYP1A2 substrates (caffeine, theophylline)

Antiretrovirals (darunavir/ritonavir, etravirine)

Immunosuppressants and biologics (ciclosporin)

Warfarin and antiplatelet agents

Over-the-counter medicines (caffeine, aspirin)

Additive immune supplements (elderberry, zinc)

Asteraceae botanicals (chamomile, feverfew)

Risk & Side Effects

High: Allergic reactions, from rash to anaphylaxis

Medium: Gastrointestinal upset; unestablished safety in pregnancy and lactation

Low: Altered blood levels of drugs cleared by liver enzymes

Speculative: Immune activation in autoimmune disease or transplantation; blunted innate immunity

Monitoring

Marker	Target	Why
Total IgE	Under 100 IU/mL	Flags the atopic phenotype at highest risk
Serum 25-hydroxyvitamin D	40–60 ng/mL	Competing determinant of infection risk
High-sensitivity C-reactive protein	Under 1.0 mg/L	Baseline inflammatory load for later change
Lymphocyte count (differential)	1.5–3.0 ×10⁹/L	Reference point for the immune-cell claims
Alanine aminotransferase	10–26 U/L women, 10–33 men	Hepatic strain in liver disease or drug clearance
Drug level or international normalised ratio	Range set for that drug	Confirms the drug has not shifted out of range

Cadence: Abnormal baselines repeat at 4 weeks and at the end of a four-month cycle; narrow-range drug levels at 2 and 6 weeks.

Qualitative Assessment

Number of distinct respiratory infections per season, against the prior season
Days of illness and days unable to train or work per episode
Peak symptom severity and whether an episode reached the sinuses or chest
Whether an episode required antibiotics
Energy and perceived recovery during and after an infection
Sleep quality and mood, given the low-dose anxiety signal
Any rash, itching, tingling, or gastrointestinal upset in the first two weeks

Echinacea for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment